This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
Zoetis (ZTS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of +8.64% and +2.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Here's Why Zoetis (ZTS) Fell More Than Broader Market
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $148.81, marking a -1.46% move from the previous day.
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Zoetis (ZTS) closed at $151.19, indicating a +2.59% shift from the previous trading day.
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
Here's Why Zoetis (ZTS) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Invest in Zoetis (ZTS) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Zoetis (ZTS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ADRNY vs. CLX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADRNY vs. CLX: Which Stock Is the Better Value Option?
GOOS vs. IDEXY: Which Stock Is the Better Value Option?
by Zacks Equity Research
GOOS vs. IDEXY: Which Stock Is the Better Value Option?
HMY or FNV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HMY vs. FNV: Which Stock Is the Better Value Option?
SGIOY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Zoetis (ZTS) closed at $155.06 in the latest trading session, marking a -4.09% move from the prior day.